Clinical Trial Market Research Reports & Industry Analysis
Clinical Trial Industry Research & Market Reports
-
Global Locally Advanced Pancreatic Cancer Market- 2022-2033
... Locally advanced pancreatic cancer refers to a stage of pancreatic cancer where the tumor is confined to the pancreas and the surrounding areas but has not spread to distant organs like the liver, lungs, or ... Read More
-
Contract Research Organization Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
... across pharmaceutical, biotechnology, and medical device sectors, alongside the rising complexity of clinical trials and personalized medicine demands. The widespread outsourcing of research activities to contract research organizations (CROs) allows companies to focus on core ... Read More
-
AI-Enabled Drug Discovery and Clinical Trials Market Report 2025-2035
... It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region. Accelerated Drug Development Timelines and Cost Efficiency Driving Market Growth Key ... Read More
-
Cell And Gene Therapy Clinical Trial Services Global Market Report 2025
... on cell and gene therapy clinical trial services market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond. ... Read More
-
Clinical Trial Imaging
... at a CAGR of 5.4% over the analysis period 2024-2030. Project & Data Management, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$472.8 Million by the ... Read More
-
Healthcare Contract Research Organization (CRO)
... Billion by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Clinical, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$68.2 Billion by ... Read More
-
e-Clinical Trial Technologies
... at a CAGR of 13.1% over the analysis period 2024-2030. Clinical Trial Management Systems (CTMS), one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$9.9 Billion by ... Read More
-
Peripheral Arterial Disease (PAD) Therapeutics
... Billion by 2030, growing at a CAGR of 6.9% over the analysis period 2024-2030. Peripheral Stents, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$1.8 Billion ... Read More
-
Biosimulation Technology
... CAGR of 15.6% over the analysis period 2024-2030. Software, one of the segments analyzed in the report, is expected to record a 14.8% CAGR and reach US$5.7 Billion by the end of the analysis period. ... Read More
-
Health Impact Report - Biotechnology & Pharmaceuticals Edition
... policy uncertainty on sustainable API sourcing and green manufacturing transitions. This report analyses thousands of sustainability disclosures from 20 leading entities in the industry, including Johnson & Johnson, Roche Holding and Pfizer. The report now ... Read More
-
B-cell Lymphoma- Pipeline Insight, 2025
... also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage B-cell Lymphoma: Understanding B-cell Lymphoma: Overview ... Read More
-
Diabetic Nephropathy- Pipeline Insight, 2025
... also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Diabetic Nephropathy: Understanding Diabetic Nephropathy: Overview ... Read More
-
Sarcopenia - Pipeline Insight, 2025
... covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Sarcopenia: Understanding Sarcopenia: Overview Sarcopenia is a ... Read More
-
Huntington’s Disease - Pipeline Insight, 2025
... It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Huntington’s Disease: Understanding Huntington’s Disease: ... Read More
-
Metastatic Colorectal Cancer - Pipeline Insight, 2025
... stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Metastatic Colorectal Cancer: ... Read More
-
Janus Kinase (JAK) Inhibitor- Pipeline Insight, 2025
... nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Janus Kinase ... Read More
-
Microbiome Disease- Pipeline Insight, 2025
... also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Microbiome Disease: Understanding Microbiome Disease: Overview ... Read More
-
Hypertriglyceridemia - Pipeline Insight, 2025
... covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography Covered Global coverage Hypertriglyceridemia: Understanding Hypertriglyceridemia: Overview Hypertriglyceridemia is a ... Read More
-
KRAS Inhibitors - Market Size, Target Population, Competitive Landscape & Market Forecast - 2034
... the United States, KRAZATI is expected to have the edge over LUMAKRAS in revenue generated during the study period (2020–2034). KRAZATI has been added as a therapeutic option after the first-line for treatment of NSCLC ... Read More
-
Oligometastatic Disease - Market Insights, Epidemiology, and Market Forecast - 2034
... to an increase in the cases and the launch of new therapies. The oligometastatic disease refers to a transitional state between localized and widespread disease. It typically involves one to five distant sites beyond the ... Read More
-
Angiotensin Receptor Agonist - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Kv1.3 Potassium Channel Blockers - Pipeline Insight, 2025
... of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the ... Read More
-
Sigma Receptor Agonist - Pipeline Insight, 2025
... pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Pipeline Products covered across the following Developmental ... Read More
-
Type 4 cyclic nucleotide phosphodiesterase inhibitors - Pipeline Insight, 2025
... drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Geography ... Read More
-
Transient Receptor Potential Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist - Pipeline Insight, 2025
... Cation Channel, Subfamily M, Member 8 (TRPM8) Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental ... Read More
Research Assistance
